Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues

Executive Summary

FDA overshot the user fee goal on Schering-Plough's Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate

You may also be interested in...



Schering-Plough’s Noxafil Clears FDA For Aspergillus Prophylaxis

Schering-Plough's Noxafil (posaconazole) is the first antifungal approved by FDA for the prevention of invasive fungal infections caused by Aspergillus species

Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings

US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count

The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel